Grant ID RP200093
Awarded On February 19, 2020
Title Targeting Multiple Myeloma Stem Cell Niche
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Nami McCarty
Cancer Sites Myeloma
Contracted Amount $900,000*

*Pending contract negotiation

Lay Summary

Multiple myeloma (MM) is a malignant B cell cancer. MM cells often elude chemotherapy and other targeted therapies by localizing to the bone marrow and entering a quiescent state. We have discovered a novel enzyme called TRIM44 that promotes MM localization and dormancy in the bone marrow and facilitates therapy resistance. In this project, we will analyze how TRIM44 contributes to MM localization and survival and develop ways to circumvent resistance to therapies. The long-term goals are to establish TRIM44 as a new therapeutic target and ultimately develop inhibitors to kill MM cells in the bone marrow and improve clinical outcomes.